NextPoint Therapeutics Receives FDA Clearance for First-in-Class B7-H7-Targeted T Cell Engager NPX372
核心洞察
NextPoint Therapeutics (搜索) has received FDA IND clearance to initiate first-in-human clinical studies of NPX372, a first-in-class T cell engager targeting the B7-H7 (搜索) axis for solid tumor treatment.
The bispecific antibody targets B7-H7 (搜索), which is highly specific to tumor epithelial cells and largely absent from normal tissue, offering a cleaner therapeutic target than existing approaches.
Preclinical studies demonstrated complete tumor regression in solid tumor models with great tolerability and no evidence of cytokine release syndrome.
NextPoint Therapeutics (搜索) announced the U.S. Food and Drug Administration has cleared an Investigational New Drug application for NPX372, marking the clinical entry of the first T cell engager targeting the B7-H7 (搜索) axis. The Cambridge-based clinical-stage biotechnology company will initiate first-in-human studies of the IgG-like CD3 (搜索) bispecific antibody designed to treat patients with solid tumors, including lung adenocarcinoma, renal cell carcinoma, and pancreatic adenocarcinoma.
Novel Target Offers Enhanced Selectivity
B7-H7 (搜索) represents a distinctive therapeutic target due to its highly specific expression on tumor epithelial cells while being largely absent from normal tissue. This expression profile sets B7-H7 apart as a cleaner and more selective target for T cell engager therapy compared to existing approaches. NPX372 is engineered as an IgG-like bispecific T cell engager designed to drive target expression-proximal cytotoxicity while minimizing non-specific T cell activation.
Promising Preclinical Results
In preclinical studies, NPX372 demonstrated complete tumor regression in solid tumor models while displaying great tolerability in relevant preclinical safety assessments. Notably, the therapy showed no evidence of cytokine release syndrome, a significant safety concern with T cell engager therapies.
"T-cell engagers represent a novel approach to delivering sustained anti-tumor immune responses to cancer patients," said Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics (搜索). "This IND clearance enables us to accelerate the delivery of targeted immune therapy to broad patient populations in need, including patients with lung adenocarcinoma, renal cell carcinoma and pancreatic adenocarcinoma."
Strategic Clinical Development Approach
The clinical program incorporates an efficient dose escalation algorithm and utilizes a novel biomarker assay to select patients with the highest chance of benefit from B7-H7 (搜索) targeting T cell engager therapy. This design enables rapid data readout and optimized dosing strategies.
"The NPX372 IND clearance represents the strategic initiation of our clinical use of B7-H7 (搜索) as a highly specific tumor-targeting antigen for potent direct tumor killing therapeutics," said Ivan Cheung, Chief Executive Officer of NextPoint Therapeutics (搜索). "The ideal expression profile of B7-H7 and the meticulous construct design of NPX372, along with a clinical trial design that enables fast and impactful data readouts, position NPX372 as a frontrunner in the emerging T cell engager field for solid tumors."
Broader B7-H7 Pipeline
NextPoint Therapeutics (搜索) is developing multiple B7-H7 (搜索)-directed therapeutic modalities beyond NPX372, including an antibody-drug conjugate with proprietary linker technology and a multi-functional checkpoint inhibitor. The company's approach integrates foundational science with defined clinical biomarkers to identify appropriate patient populations for each B7-H7-directed therapy, targeting cancer patients with B7-H7 upregulation who may not benefit from currently approved therapies such as PD-1/L1 inhibitors.